Brief: Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
12/08/2024 14:07
Aug 12 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS, INC. ANNOUNCES CONCUSSION DRUG SUCCESSFULLY
COMPLETES
FDA-REQUIRED GENOTOXICITY STUDY
* PHASE II CLINICAL TRIAL BEING PLANNED
* ONP-002 SHOWED NO CANCER-CAUSING DNA DAMAGE
Source text for Eikon: ID:nGNX6mnNPd
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing